cbd3 peptide TAT-CBD3 proved effective in ameliorating the hypersensitivity - collagen-peptides-benefits-for-women CBD3 The Multifaceted Potential of the CBD3 Peptide: A Novel Approach to Pain Management and Neuroprotection

carved-peptide-blend The CBD3 peptide, a sequence derived from the collapsin response mediator protein 2 (CRMP-2), has emerged as a significant area of research in the pursuit of novel therapeutic strategies for neuropathic pain and neurodegenerative conditions. This 15-amino acid peptide, also referred to as the Ca(2+) channel-binding domain 3 (CBD3) peptide, acts by targeting voltage-gated calcium channels, specifically CaV2.2, and disrupting their interaction with CRMP-2.作者：A Moutal·2015·被引用次数：50—Our results demonstrate that altering CPPs can bestow differential neuroprotective potential onto theCBD3cargo. This interaction is crucial for the influx of calcium ions into neurons, a process implicated in the transmission of pain signals and neuronal excitability作者：AD Piekarz·2012·被引用次数：56—We previously identified a peptide, designatedCBD3, that suppressed inflammatory and neuropathic behavioral hypersensitivity in rodents by ....

Research has consistently demonstrated the efficacy of the CBD3 peptide in preclinical models. For instance, studies have shown that CBD3 can significantly reduce neuropathic pain behaviors in rodents. Its mechanism of action involves uncoupling CRMP-2 from CaV2.2 channels, leading to a decrease in calcium currents. This targeted approach offers a promising alternative to conventional pain medications.Further insights into the antinociceptive potential of a ... In some instances, compounds based on the CBD3 peptide have shown to have outperformed gabapentin in preclinical studies, notably without the troublesome side effects often associated with gabapentinA PEPTIDE UNCOUPLING CRMP-2 FROM THE ... - PubMed. This suggests a potential for more refined and safer pain management.

Various modifications and delivery systems have been explored to optimize the therapeutic potential of the CBD3 peptide作者：K Gomez·2023·被引用次数：30—CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Ca v 2.2 to achieve analgesia and pain relief.. One such modification is the TAT-CBD3 peptide, which incorporates the TAT cell-penetrating motif from the HIV-1 protein. This fusion enhances the peptide's ability to enter cells, thereby increasing its bioavailability and therapeutic impact. Studies have shown that TAT-CBD3 effective in ameliorating hypersensitivity associated with various rodent models of chronic inflammatory and neuropathic pain states. Furthermore, systemic injection of CBD3 peptide conjugated with the TAT motif has demonstrated a reduction in hypersensitivity in animal models. Another variant, myr-tat-CBD3, features an N-terminal myristoylated version, further improving its membrane association and efficacy.作者：Y Yao·2021·被引用次数：12—... (CBD3) peptide, that conferred protection against excitotoxicity and traumatic brain injury. ST2-104, a nona-arginine (R9)-fused CBD3 peptide, exerted ...

Beyond its direct application as a peptide, the CBD3 peptide has also served as a template for the development of peptidomimetic small molecules. A prime example is CBD3063, described as a selective, first-in-class, CRMP2-based peptidomimetic small molecule.Neither peptide altered surface trafficking of NMDARs. Neuroprotection conferred by MTS-CBD3 peptideis likely due to its increased uptake coupled with decreased efflux when compared to TAT-CBD3. Overall, our results demonstrate that altering CPPs can bestow differential neuroprotective potential onto the CBD3 cargo. CBD3063 allosterically regulates CaV2.AAV-encoded CaV2.2 peptide aptamer CBD3A6K for ...2 channels to achieve analgesia and pain relief. This innovation broadens the scope of therapeutic interventions targeting the CRMP-2 and CaV2.TAT-CBD3 is the 15-amino acid peptidederived from the axonal collapsin response mediator protein 2 (CRMP-2) conjugated to the cell penetrating motif of the HIV ...2 pathway.

The neuroprotective capabilities of the CBD3 peptide are also a significant area of investigation作者：A Moutal·2018·被引用次数：48—A 15-amino-acidpeptide(CBD3), derived from CRMP2, disrupts the functional protein–protein interaction between CRMP2 and Cav2.2 channels to .... Research indicates that CBD3 peptide can confer protection against excitotoxicity and traumatic brain injury. For example, ST2-104, a nonararginine (R9)-fused CBD3 peptide, has shown potent neuroprotective effects.New Compound Outperforms Pain Drug by Indirectly ... Variants such as TAT-CBD3A6K, a modified TAT-CBD3 peptide, have been shown to reduce T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons, a key component in pain signaling. The application of CBD3 in vivo has been observed to attenuate pain behaviors in animal models by reducing inward Ca2+ currents through the CaV2.2α1b subunit via block.

The mechanism of action for the CBD3 peptide typically involves disrupting the interaction between CRMP-2 and CaV2.Sustained relief of neuropathic pain by AAV-targeted ...2 channels. This disruption leads to decreased CaV2.2 surface localization and reduced calcium currents. These alterations primarily occur at presynaptic sites of nociceptive pathways. Notably, attaching R9 to CBD3 has yielded a peptide that is more effective than TAT-CBD3, suggesting that the choice of cell-penetrating peptide can influence the overall therapeutic outcome. Application of a CBD3 peptide lacking the TAT cell-penetrating sequence did not always demonstrate the same level of protection, highlighting the importance of delivery mechanisms.

Further research has explored the modulation of N-methyl-D-aspartate receptors (NMDARs) in conjunction with CBD3Homology‐guided mutational analysis reveals the functional .... TAT-CBD3, a 15-amino acid peptide derived from CRMP2, when fused with the TAT cell-penetrating motif, disrupts the CRMP2-NMDAR interaction. This disruption occurs without altering NMDAR localization, suggesting a nuanced role beyond simple channel blockadeNew Compound Outperforms Pain Drug by Indirectly .... In some contexts, CBD3 uncouples CRMP2–CaV2Myr-tat-CBD3 | Myr-YGRKKRRQRRRARSRLAELRGVPRGL.2 binding to decrease CaV2.2 surface localization and calcium currents.

The broader implications of targeting the CRMP-2 pathway with peptides like CBD3 extend to various neurological conditions. The ability to selectively modulate calcium channel activity and protein interactions offers a promising avenue for developing treatments that address the underlying mechanisms of pain and neurodegeneration, providing sustained relief of neuropathic pain. The continuous development of modified peptides and peptidomimetics, such as TAT-CBD3A6K and others, underscores the significant and evolving therapeutic potential of the CBD3 peptide and its derivatives.